Form D · Other
Insignis Therapeutics Inc.
North Haven, CT · CIK 0001981826
Offering snapshot reported Aug 5, 2026 · SEC filing
- Reported sold
- $6M Offering amount: $8.5M
- Investors reported
- 4 Form D · investor count
- Minimum accepted
- $1 Reported outside-investor minimum
- First sale
- Jun 11, 2026 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 5, 2026 | Initial | $5,999,714 | No comparison | 4 | SEC filing |
| Jun 16, 2023 | Initial | $500,000 | No comparison | 1 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593201
Source: Form D, filed Aug 5, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Mingbao Zhang | Director, Executive |
Issuer details
Industry: Other (See others in industry)
Address:
410 Sackett Point Road Building 20
North Haven, CT, 06473
North Haven, CT, 06473